FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053327646> ?p ?o ?g. }

• W2053327646 endingPage "886.e1" @default.
• W2053327646 startingPage "876" @default.
• W2053327646 abstract "Purpose To investigate the efficacy and safety of intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2. Design Prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. Methods One eye (disease stage 2 or 3) of each patient (n = 10) with nonproliferative MacTel type 2 was injected with 0.5 mg ranibizumab at monthly intervals for one year. Visual acuity, angiographic findings, and retinal thickness were assessed at each visit. The primary endpoint was the change in best-corrected distance visual acuity after one year compared to baseline. Results Mean visual acuity showed a transient increase in the study eye. However, after 12 months of treatment there was no significant change of visual acuity compared to baseline or compared to the fellow eye. Fluorescein angiography revealed a decrease of telangiectatic-appearing capillaries and of late-phase leakage, which was accompanied by a topographically related significant reduction in macular thickness. Three to 5 months after the last treatment, angiographic appearance and retinal thickness were similar to baseline. In one patient, the last intravitreal injection was not performed because of safety concerns after a transitory ischemic attack. Otherwise, no serious adverse events were observed. Conclusions The angiographic and tomographic effects after intravitreal inhibition of vascular endothelial growth factor (VEGF) using ranibizumab implicate a pathophysiological role of the VEGF pathway in nonproliferative MacTel type 2. As the morphologic response was not associated with a clear functional benefit, and because of the transient nature of the treatment effect, monthly intravitreal ranibizumab is not recommended for the nonproliferative disease stage of MacTel type 2. To investigate the efficacy and safety of intravitreal ranibizumab for the treatment of nonproliferative macular telangiectasia (MacTel) type 2. Prospective, open-label, uncontrolled, nonrandomized interventional clinical trial. One eye (disease stage 2 or 3) of each patient (n = 10) with nonproliferative MacTel type 2 was injected with 0.5 mg ranibizumab at monthly intervals for one year. Visual acuity, angiographic findings, and retinal thickness were assessed at each visit. The primary endpoint was the change in best-corrected distance visual acuity after one year compared to baseline. Mean visual acuity showed a transient increase in the study eye. However, after 12 months of treatment there was no significant change of visual acuity compared to baseline or compared to the fellow eye. Fluorescein angiography revealed a decrease of telangiectatic-appearing capillaries and of late-phase leakage, which was accompanied by a topographically related significant reduction in macular thickness. Three to 5 months after the last treatment, angiographic appearance and retinal thickness were similar to baseline. In one patient, the last intravitreal injection was not performed because of safety concerns after a transitory ischemic attack. Otherwise, no serious adverse events were observed. The angiographic and tomographic effects after intravitreal inhibition of vascular endothelial growth factor (VEGF) using ranibizumab implicate a pathophysiological role of the VEGF pathway in nonproliferative MacTel type 2. As the morphologic response was not associated with a clear functional benefit, and because of the transient nature of the treatment effect, monthly intravitreal ranibizumab is not recommended for the nonproliferative disease stage of MacTel type 2." @default.
• W2053327646 created "2016-06-24" @default.
• W2053327646 creator A5016922490 @default.
• W2053327646 creator A5059328359 @default.
• W2053327646 creator A5071189657 @default.
• W2053327646 creator A5073328427 @default.
• W2053327646 creator A5073703088 @default.
• W2053327646 creator A5079292802 @default.
• W2053327646 date "2011-05-01" @default.
• W2053327646 modified "2023-09-27" @default.
• W2053327646 title "Monthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study" @default.
• W2053327646 cites W1572073544 @default.
• W2053327646 cites W1949900595 @default.
• W2053327646 cites W1970142574 @default.
• W2053327646 cites W1970789407 @default.
• W2053327646 cites W1973002638 @default.
• W2053327646 cites W1979047354 @default.
• W2053327646 cites W1981702879 @default.
• W2053327646 cites W1985972159 @default.
• W2053327646 cites W1990211981 @default.
• W2053327646 cites W1994621369 @default.
• W2053327646 cites W1994975972 @default.
• W2053327646 cites W1995443671 @default.
• W2053327646 cites W2006202253 @default.
• W2053327646 cites W2008810667 @default.
• W2053327646 cites W2011837887 @default.
• W2053327646 cites W2013855450 @default.
• W2053327646 cites W2018784138 @default.
• W2053327646 cites W2024725915 @default.
• W2053327646 cites W2026747391 @default.
• W2053327646 cites W2026791298 @default.
• W2053327646 cites W2035178655 @default.
• W2053327646 cites W2036010344 @default.
• W2053327646 cites W2038749437 @default.
• W2053327646 cites W2038978104 @default.
• W2053327646 cites W2040362105 @default.
• W2053327646 cites W2046071775 @default.
• W2053327646 cites W2052188656 @default.
• W2053327646 cites W2057646945 @default.
• W2053327646 cites W2059694718 @default.
• W2053327646 cites W2060269010 @default.
• W2053327646 cites W2061743920 @default.
• W2053327646 cites W2067626374 @default.
• W2053327646 cites W2068155134 @default.
• W2053327646 cites W2068416568 @default.
• W2053327646 cites W2073148412 @default.
• W2053327646 cites W2075198919 @default.
• W2053327646 cites W2076661975 @default.
• W2053327646 cites W2077129920 @default.
• W2053327646 cites W2083529438 @default.
• W2053327646 cites W2085712747 @default.
• W2053327646 cites W2093536592 @default.
• W2053327646 cites W2104525395 @default.
• W2053327646 cites W2124415048 @default.
• W2053327646 cites W2130134664 @default.
• W2053327646 cites W2171524333 @default.
• W2053327646 cites W2471512077 @default.
• W2053327646 cites W2606279994 @default.
• W2053327646 cites W4294255520 @default.
• W2053327646 cites W63783617 @default.
• W2053327646 doi "https://doi.org/10.1016/j.ajo.2010.11.019" @default.
• W2053327646 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21334595" @default.
• W2053327646 hasPublicationYear "2011" @default.
• W2053327646 type Work @default.
• W2053327646 sameAs 2053327646 @default.
• W2053327646 citedByCount "52" @default.
• W2053327646 countsByYear W20533276462012 @default.
• W2053327646 countsByYear W20533276462013 @default.
• W2053327646 countsByYear W20533276462014 @default.
• W2053327646 countsByYear W20533276462015 @default.
• W2053327646 countsByYear W20533276462016 @default.
• W2053327646 countsByYear W20533276462017 @default.
• W2053327646 countsByYear W20533276462018 @default.
• W2053327646 countsByYear W20533276462019 @default.
• W2053327646 countsByYear W20533276462020 @default.
• W2053327646 countsByYear W20533276462021 @default.
• W2053327646 countsByYear W20533276462022 @default.
• W2053327646 crossrefType "journal-article" @default.
• W2053327646 hasAuthorship W2053327646A5016922490 @default.
• W2053327646 hasAuthorship W2053327646A5059328359 @default.
• W2053327646 hasAuthorship W2053327646A5071189657 @default.
• W2053327646 hasAuthorship W2053327646A5073328427 @default.
• W2053327646 hasAuthorship W2053327646A5073703088 @default.
• W2053327646 hasAuthorship W2053327646A5079292802 @default.
• W2053327646 hasConcept C118487528 @default.
• W2053327646 hasConcept C126322002 @default.
• W2053327646 hasConcept C141071460 @default.
• W2053327646 hasConcept C168563851 @default.
• W2053327646 hasConcept C188816634 @default.
• W2053327646 hasConcept C197934379 @default.
• W2053327646 hasConcept C203092338 @default.
• W2053327646 hasConcept C2776148792 @default.
• W2053327646 hasConcept C2776330896 @default.
• W2053327646 hasConcept C2776694085 @default.
• W2053327646 hasConcept C2777802072 @default.
• W2053327646 hasConcept C2778075232 @default.
• W2053327646 hasConcept C2778257484 @default.
• W2053327646 hasConcept C2780248432 @default.

• next